Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDT
Company Participants
Susie Lisa – Senior Vice President of Investor Relations
Reshma Kewalramani – CEO, President & Director
Duncan J. McKechnie – Chief Commercial Officer, Head of North America Commercial & Executive VP
Charles Wagner – Executive VP, COO & CFO
Conference Call Participants
Salveen Richter – Goldman Sachs Group, Inc., Research Division
Geoffrey Meacham – Citigroup Inc., Research Division
Jessica Fye – JPMorgan Chase & Co, Research Division
Cory Kasimov – Evercore ISI Institutional Equities, Research Division
Brian Abrahams – RBC Capital Markets, Research Division
Evan Seigerman – BMO Capital Markets Equity Research
Michael Yee – UBS Investment Bank, Research Division
Tazeen Ahmad – BofA Securities, Research Division
Philip Nadeau – TD Cowen, Research Division
Terence Flynn – Morgan Stanley, Research Division
Mohit Bansal – Wells Fargo Securities, LLC, Research Division
Eliana Merle – Barclays Bank PLC, Research Division
Presentation
Operator
Good day, and welcome to the Vertex Pharmaceuticals Second Quarter 2026 Earnings Call. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead.
Susie Lisa
Senior Vice President of Investor Relations
Good evening, all. My name is Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our Second Quarter 2026 Financial Results Conference Call. On tonight’s call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex’s CEO and President; Charlie Wagner, Chief Operating Officer and Chief Financial Officer; and Duncan McKechnie, Chief Commercial Officer. We recommend that you access the webcast slides as you listen to this call. The call is being recorded, and a replay will be available on our website.
We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail
